Company Presentation

Vandria SA

Category:Emerging Biotech Company
Date:April 25, 2023
Speaker:Dr. Klaus Dugi, CEO

Company profile

Vandria develops novel small molecules induce mitophagy to treat age-related and chronic diseases.
The company is in the the IND-enabling stage targeting:
• CNS: Mild Cognitive Impairment, ALS
• Muscle: Sporadic Inclusion Body Myositis
• Other: Immuno-oncology, IPF, NASH

Vandria is seeking additional investors to complete its Series A financing round of EUR 14 million led by ND Capital. We also seek partners for our new ferroptosis program.